HLA-G and cancer: While checkpoint blocking is a dramatic new approach to cancer immunotherapy, it is limited to a relatively small subset of cancers and, of course, also limited by the development of resistance to the therapy due to selection for β2 microglobulin and other mutations that interfere with T cell immune responses.